Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × anlotinib × CNS × Clear all

Phase

Status

Unknown 7 Recruiting 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 17 Gastrointestinal 6 Head & Neck 3 Sarcoma 2 Breast 2 Tumor-Agnostic 1 Other solid neoplasm 1 Gynecologic 1 Genitourinary 1 Dermatologic 1 CNS 1

Conditions

Brain Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

Temozolomide 18 Magnetic Resonance Spectroscopy 8 Blood Specimen Collection 8 Radiotherapy 7 Cyclophosphamide 6 Bevacizumab 6 AZD 6244 6 pembrolizumab 5 aflutinib 4 fludarabine 3 Specimen Handling 3 Radiation 3 Pemetrexed 3 Biopsy 3 vorasidenib 2 tovorafenib 2 tislelizumab 2 osimertinib 2 fludarabine phosphate 2 dinutuximab 2 Topotecan 2 Surveys and Questionnaires 2 Surgical Procedures, Operative 2 Radiotherapy, Intensity-Modulated 2 Radiosurgery 2 Nivolumab 2 Lomustine 2 Indocyanine Green 2 Granulocyte-Macrophage Colony-Stimulating Factor 2 Craniotomy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06483672 2024-07-03

LungBrain001

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting

Adenocarcinoma of Lung, Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡